2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation

. 2021 Apr 25;23(10):1612–1676. doi: 10.1093/europace/euab065

Treatment of DVT/PE

	Initial therapy	Remainder of treatment phase
Apixaban⁴⁹⁸	10 mg BID, 7 days	5 mg BID, no dose reduction
Dabigatran⁴⁹⁹	Heparin/LMWH	150 mg BID, no dose reduction^a
Edoxaban⁵⁰⁰	Heparin/LMWH	60 mg QD, same dose reduction as for SPAF (see above)
Rivaroxaban⁵⁰¹^,⁵⁰²	15 mg BID, 21 days	20 mg QD, no dose reduction^b

BID, twice daily; GI, gastrointestinal; LMWH, low molecular weight heparin; QD, once daily; SPAF, stroke prevention in atrial fibrillation.

Per SmPC: 110 mg BID if age ≥80 years, concomitant verapamil, increased risk of GI bleeding [based on pharmacokinetic/pharmacodynamic (PK/PD) analyses; not studied in this setting].

Per SmPc: 15 mg if risk of bleeding outweighs risk for recurrent DVT and PE (based on PK/PD analyses; not studied in this setting).